71011 20180622124306.0 doi 10.1089/mdr.2013.0109 sideral 85992 ART-2014-85992 eng Garrido, A. Characterization of plasmid-mediated beta-lactamases in fecal colonizing patients in the hospital and community setting in Spain 2014 Access copy available to the general public Unrestricted Aim: Active surveillance of plasmid-mediated ß-lactamase-producing Enterobacteriaceae (PMBL-E) in fecal carriers in the hospital and in the community setting in a non-outbreak period of time. Methods: Patients were screened for carriage of Enterobacteriaceae resistant to expanded-spectrum cephalosporins and PMBL-E were characterized (extended-spectrum-ß-lactamase [ESBL], plasmid-mediated AmpC ß-lactamase [pAmpC], and carbapenemases) by PCR and sequencing. Results: The prevalence of ESBL and pAmpC carriers was 5.06% and 0.59%, respectively. Overall, CTX-M-like enzymes were the ESBL dominate enzymes (96.15%). The group CTX-M-9 was the most prevalent (81, 54%) [CTX-M-14 (74, 91.35%), CTX-M-9 (5, 6.17%), CTX-M-24 (1, 1.23%), and CTX-M-27 (1, 1.23%)] followed by the group CTX-M-1 (64, 42.67%) [CTX-M-15 (42, 65.63%), CTX-M-1 (13, 20.31%), CTX-M-32 (8, 12.5%), and CTX-M-3 (1, 1.56%)]. One CTX-M-10, one CTX-M-59, and three CTX-M-8 were also found. A very small representation of SHV or TEM ESBL enzymes was found (3.2% and 0.64%, respectively). pAmpC characterization revealed a predominance of CMY-2 (81.25%), followed by DHA-1 (18.75%). We did not detect the presence of carbapenemase producers. Conclusions: The prevalence of ESBL-producers from fecal carriers is stable in our area, but colonization by pAmpC producers has emerged recently as we have confirmed. Periodic active surveillance is useful to identify these human reservoirs and control the evolution of PMBL carriage in a community over time. info:eu-repo/grantAgreement/ES/DGA/B24-211130 info:eu-repo/semantics/openAccess All rights reserved http://www.europeana.eu/rights/rr-f/ 2.49 2014 PHARMACOLOGY & PHARMACY 116 / 255 = 0.455 2014 Q2 T2 INFECTIOUS DISEASES 42 / 78 = 0.538 2014 Q3 T2 MICROBIOLOGY 62 / 119 = 0.521 2014 Q3 T2 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion (orcid)0000-0002-9742-1463 Seral, C. Universidad de Zaragoza Gude, M.J. Casado, C. González-Domínguez, M. Sáenz, Y. (orcid)0000-0002-2519-701X Castillo F.J. Universidad de Zaragoza 1008 630 Universidad de Zaragoza Departamento de Microbiología, Medicina Preventiva y Salud Pública Microbiología 20, 4 (2014), 301-304 Microb. drug resist. Microbial Drug Resistance 1076-6294 118274 http://zaguan.unizar.es/record/71011/files/texto_completo.pdf Versión publicada 109176 http://zaguan.unizar.es/record/71011/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:71011 articulos driver 2018-06-22-11:08:29 ARTICLE